Editorial Policy
Last updated: 28 May 2026
The BioPharma Intelligence Hub is committed to providing accurate, transparent, and independent analysis of drug pipeline data from publicly available U.S. government sources. This Editorial Policy governs how we source, process, present, and correct information.
1. Data Sources and Methodology
All data presented on the BioPharma Intelligence Hub is sourced from publicly available U.S. government databases and official regulatory filings. We do not use proprietary, paywalled, or non-public data sources.
Primary Data Sources
- FDA.gov U.S. Food and Drug Administration -- PDUFA target action dates, drug approvals, Complete Response Letters (CRLs), Advisory Committee (AdCom) meeting schedules and results, warning letters, drug recalls, Breakthrough Therapy designations, Fast Track designations, Priority Review grants, and Orange Book data. (Public domain)
- SEC EDGAR U.S. Securities and Exchange Commission -- Annual reports (10-K), quarterly reports (10-Q), current reports (8-K), proxy statements (DEF 14A), and other public filings for pipeline-related disclosures.
- ClinicalTrials.gov National Library of Medicine -- Clinical trial registrations, study designs, enrollment status, primary endpoints, results postings, and study completion data.
- DailyMed National Institutes of Health -- Approved drug labeling, prescribing information, and medication guides.
Data Collection Process
- Data is fetched from source APIs and databases at regular intervals (frequency varies by source)
- Raw data is normalized and structured into our internal database schema
- Automated validation checks flag data anomalies for review
- Changes in regulatory status (new approvals, CRLs, PDUFA date changes) are detected and reflected on the Platform
2. Pipeline Grading Methodology
Pipeline grades (A+ through D) are computed using a transparent, rules-based algorithm. The methodology evaluates multiple dimensions of a company's drug pipeline and regulatory standing.
Grading Factors
The pipeline grade for each company is determined by evaluating the following factors:
- Pipeline stage distribution: Percentage of drug candidates in late-stage (Phase 3, NDA/BLA filed) vs. early-stage (Phase 1, Phase 2) development
- Regulatory milestones: Number and proximity of upcoming PDUFA dates, AdCom meetings, and regulatory decisions
- Approval track record: Historical FDA approval rate for the company's applications
- Catalyst density: Number of near-term regulatory and clinical catalysts
- Designation advantages: Breakthrough Therapy, Fast Track, Priority Review, Orphan Drug, and Accelerated Approval designations
- Risk indicators: Complete Response Letters, clinical holds, warning letters, and drug recalls
Grade Definitions
| Grade | Meaning | Analytical Interpretation |
|---|---|---|
| A+ | Exceptional pipeline | Strong late-stage pipeline with multiple near-term catalysts, favorable regulatory designations, and minimal risk indicators |
| A | Strong pipeline | Robust pipeline with meaningful late-stage assets, positive regulatory trajectory, and manageable risk profile |
| B | Moderate pipeline | Mixed pipeline with some late-stage assets but limited near-term catalysts or moderate risk indicators present |
| C | Weak pipeline | Predominantly early-stage pipeline, limited regulatory milestones, or notable risk indicators such as CRLs or clinical holds |
| D | High-risk pipeline | Minimal active pipeline, significant regulatory setbacks (multiple CRLs, warning letters), or major unresolved safety concerns |
Pipeline grades are analytical assessments of drug development progress. They are NOT investment ratings, stock recommendations, or predictions of stock price movement. See our full Disclaimer.
3. AI Content Generation and Fact-Checking
The BioPharma Intelligence Hub uses Google Gemini, a large language model, to generate certain types of content. Our AI content process is designed for transparency and accuracy.
What AI Generates
- Company pipeline summaries: Narrative overviews of a company's drug development activities and regulatory status
- Catalyst context: Explanatory text providing background on regulatory events and their significance
- Data interpretations: Textual explanations of quantitative data points drawn from FDA, SEC, and clinical trial sources
What AI Does NOT Generate
- Pipeline grades (these are computed algorithmically from structured data)
- PDUFA dates, approval dates, or regulatory event data (sourced directly from FDA)
- Clinical trial data (sourced directly from ClinicalTrials.gov)
- SEC filing data (sourced directly from EDGAR)
- Investment advice or recommendations of any kind
Labeling and Transparency
All AI-generated content is clearly labeled with an "AI-generated" indicator. Users can always distinguish between data sourced directly from government databases and content generated by AI. The AI model (Google Gemini) is identified on every page where AI-generated content appears.
Fact-Checking Process
- Source grounding: AI prompts include structured data from our database to ground the model's output in verified facts
- Output constraints: The AI is instructed to generate only factual summaries based on the provided data, not speculative or forward-looking statements
- Automated validation: Key facts in AI output (company names, drug names, regulatory statuses) are cross-checked against our structured database
- Source linking: Where possible, AI-generated summaries include links to the original data sources for user verification
Despite these safeguards, AI-generated content may contain errors, omissions, or outdated information. Users should always verify critical information against the linked primary sources.
4. Editorial Independence
The BioPharma Intelligence Hub maintains strict editorial independence:
- No compensation from covered companies: MarketsHost does not receive payment, sponsorship, consulting fees, or any form of compensation from any pharmaceutical, biotechnology, or life sciences company whose pipeline or data appears on this Platform
- No advertising influence: Editorial content and pipeline grades are never influenced by advertising relationships or business partnerships
- No conflicts of interest: Team members involved in data processing, grade computation, and editorial content do not trade in the securities of companies covered on the Platform during their tenure
- Algorithmic objectivity: Pipeline grades are computed using the same methodology for all companies, without manual adjustment or editorial override
- No pay-for-coverage: Companies cannot pay to be listed, de-listed, or to receive a particular grade on the Platform
5. Error Correction Process
We are committed to correcting errors promptly and transparently:
Types of Corrections
- Data corrections: Errors in regulatory data, clinical trial information, or company details sourced from government databases are corrected as soon as updated source data is available
- Grade corrections: If a pipeline grade is found to have been computed based on incorrect or incomplete data, the grade is recalculated and updated
- AI content corrections: Factual errors in AI-generated summaries are corrected or the content is regenerated with accurate data
- Editorial corrections: Errors in original editorial content are corrected with a note indicating what was changed and when
Correction Timeline
- Critical data errors (incorrect regulatory status, wrong PDUFA date): Corrected within 24 hours of discovery
- Non-critical data errors (minor factual inaccuracies in summaries): Corrected within 72 hours
- Grade recalculations due to data corrections: Processed in the next scheduled update cycle
6. Source Citation Standards
The BioPharma Intelligence Hub follows these citation standards:
- All data points derived from government sources include a link or reference to the original source where feasible
- FDA data references include the relevant FDA webpage, press release, or database entry
- ClinicalTrials.gov data includes the NCT (National Clinical Trial) identifier
- SEC filings reference the specific filing type and date
- When exact source links are not available, the source database and query parameters used are indicated
- AI-generated content is attributed to the AI model used (Google Gemini) and is clearly distinguished from source data
7. How to Report Errors
We welcome reports of errors, inaccuracies, or outdated information from our users. If you identify an error on the Platform, please report it through any of the following channels:
- Email: [email protected] with the subject line "Data Correction Request"
- Details to include: The URL of the page containing the error, a description of the error, the correct information (if known), and the source supporting the correction
We will acknowledge error reports within 24 hours and investigate each report. If a correction is warranted, we will update the Platform according to the correction timeline outlined above. If no correction is needed, we will explain our reasoning to the reporter.